Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
NBIO .102 - As of February 11, 2020 , the Registrant had 36,160,870 shares of common stock issued and outstanding.
For the three and nine month periods ended December 31, 2019, our net loss was $370,152 and $975,746 compared to a net loss of $256,565 and $1,034,282 for the same periods in 2018.
https://www.otcmarkets.com/filing/html?id=13902840&guid=7kPFUFTR10xDZth
The Q4-filing is due by 6/30. I'll be looking to see if they have held/can hold the quarterly monetary burn rate at a comparable rate of 4M dilution?
This covid-biotech has no FUNDAMENTAL PEER in market-cap price comparison? The risk/reward oppurtunity here is literally off-the-charts...
NBIO .102 - As of February 11, 2020 , the Registrant had 36,160,870 shares of common stock issued and outstanding.
For the three and nine month periods ended December 31, 2019, our net loss was $370,152 and $975,746 compared to a net loss of $256,565 and $1,034,282 for the same periods in 2018.
https://www.otcmarkets.com/filing/html?id=13902840&guid=7kPFUFTR10xDZth
The Q4-filing is due by 6/30. I'll be looking to see if they have held/can hold the quarterly monetary burn rate at a comparable rate of 4M dilution?
This covid-biotech has no FUNDAMENTAL PEER in market-cap price comparison? The risk/reward oppurtunity here is literally off-the-charts...
As of February 11, 2020 , the Registrant had 36,160,870 shares of common stock issued and outstanding.
For the three and nine month periods ended December 31, 2019, our net loss was $370,152 and $975,746 compared to a net loss of $256,565 and $1,034,282 for the same periods in 2018.
https://www.otcmarkets.com/filing/html?id=13902840&guid=7kPFUFTR10xDZth
The Q4-filing is due by 6/30. I'll be looking to see if they have held/can hold the quarterly monetary burn rate at a comparable rate of 4M dilution?
This covid-biotech has no FUNDAMENTAL PEER in market-cap price comparison? The risk/reward oppurtunity here is literally off-the-charts...
SAN DIEGO, June 17, 2020 (GLOBE NEWSWIRE) -- Nascent Biotech, Inc. (OTCQB: NBIO), today announced after receiving early In-Vitro study results Pritumumab, (PTB), will be advanced to laboratory-based animal studies. Nascent founder and Advisory Board Chairman Dr. Mark Glassy commented, “The laboratory results were consistent with our Brain Cancer in vitro studies and this is the next step in investigational development of PTB as potential use with COVID-19 and related Viral Infections.”
An article in The Journal of Biological Medicine (Yu et al. Journal of Biomedical Science (2016) 23:14 DOI 10.1186/s12929-016-0234-7) specifically mentioned cell surface vimentin as a potential target in the treatment of conditions related to the Coronavirus which was instrumental in Nascent’s investigation into Viral Infections.
Nascent’s Management is continuing development in Viral Infections along with opening the Phase I Brain Cancer Clinical Trial at Hoag Family Cancer Institute and Pickup Family Neurosciences Institute Presbyterian.
https://www.otcmarkets.com/stock/NBIO/news/Nascent-Biotech-to-Begin-Animal-Model-Studies-for-Pritumumab-Against-Coronaviruses-and-COVID-19?id=265045
NBIO .1075 - Nascent Biotech to Begin Animal Model Studies for Pritumumab Against Coronaviruses and COVID-19
SAN DIEGO, June 17, 2020 (GLOBE NEWSWIRE) -- Nascent Biotech, Inc. (OTCQB: NBIO), today announced after receiving early In-Vitro study results Pritumumab, (PTB), will be advanced to laboratory-based animal studies. Nascent founder and Advisory Board Chairman Dr. Mark Glassy commented, “The laboratory results were consistent with our Brain Cancer in vitro studies and this is the next step in investigational development of PTB as potential use with COVID-19 and related Viral Infections.”
An article in The Journal of Biological Medicine (Yu et al. Journal of Biomedical Science (2016) 23:14 DOI 10.1186/s12929-016-0234-7) specifically mentioned cell surface vimentin as a potential target in the treatment of conditions related to the Coronavirus which was instrumental in Nascent’s investigation into Viral Infections.
Nascent’s Management is continuing development in Viral Infections along with opening the Phase I Brain Cancer Clinical Trial at Hoag Family Cancer Institute and Pickup Family Neurosciences Institute Presbyterian.
https://www.otcmarkets.com/stock/NBIO/news/Nascent-Biotech-to-Begin-Animal-Model-Studies-for-Pritumumab-Against-Coronaviruses-and-COVID-19?id=265045
NBIO .1075 - Nascent Biotech to Begin Animal Model Studies for Pritumumab Against Coronaviruses and COVID-19
SAN DIEGO, June 17, 2020 (GLOBE NEWSWIRE) -- Nascent Biotech, Inc. (OTCQB: NBIO), today announced after receiving early In-Vitro study results Pritumumab, (PTB), will be advanced to laboratory-based animal studies. Nascent founder and Advisory Board Chairman Dr. Mark Glassy commented, “The laboratory results were consistent with our Brain Cancer in vitro studies and this is the next step in investigational development of PTB as potential use with COVID-19 and related Viral Infections.”
An article in The Journal of Biological Medicine (Yu et al. Journal of Biomedical Science (2016) 23:14 DOI 10.1186/s12929-016-0234-7) specifically mentioned cell surface vimentin as a potential target in the treatment of conditions related to the Coronavirus which was instrumental in Nascent’s investigation into Viral Infections.
Nascent’s Management is continuing development in Viral Infections along with opening the Phase I Brain Cancer Clinical Trial at Hoag Family Cancer Institute and Pickup Family Neurosciences Institute Presbyterian.
https://www.otcmarkets.com/stock/NBIO/news/Nascent-Biotech-to-Begin-Animal-Model-Studies-for-Pritumumab-Against-Coronaviruses-and-COVID-19?id=265045
NBIO .1075 - Nascent Biotech to Begin Animal Model Studies for Pritumumab Against Coronaviruses and COVID-19
SAN DIEGO, June 17, 2020 (GLOBE NEWSWIRE) -- Nascent Biotech, Inc. (OTCQB: NBIO), today announced after receiving early In-Vitro study results Pritumumab, (PTB), will be advanced to laboratory-based animal studies. Nascent founder and Advisory Board Chairman Dr. Mark Glassy commented, “The laboratory results were consistent with our Brain Cancer in vitro studies and this is the next step in investigational development of PTB as potential use with COVID-19 and related Viral Infections.”
An article in The Journal of Biological Medicine (Yu et al. Journal of Biomedical Science (2016) 23:14 DOI 10.1186/s12929-016-0234-7) specifically mentioned cell surface vimentin as a potential target in the treatment of conditions related to the Coronavirus which was instrumental in Nascent’s investigation into Viral Infections.
Nascent’s Management is continuing development in Viral Infections along with opening the Phase I Brain Cancer Clinical Trial at Hoag Family Cancer Institute and Pickup Family Neurosciences Institute Presbyterian.
https://www.otcmarkets.com/stock/NBIO/news/Nascent-Biotech-to-Begin-Animal-Model-Studies-for-Pritumumab-Against-Coronaviruses-and-COVID-19?id=265045
The problem with shorting an MHH is it offers no "put" option trading for when a stock just continues going the wrong direction and one needs to triple-down without risking the entire gangsta-roll. jmo
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=156076930
Some validity to that, but the over-the-top BULLYING don't work.
COMPROMISE is a grey-area human condition, neither black nor white.
And the mayor of Seattle is a certified spaceball...
Huge fundamental difference between HTBX and NBIO...
Market Cap = $67M
Quarterly Burn = $6.3M
https://www.otcmarkets.com/filing/html?id=14154859&guid=6h9FUecOelEKEth
Market Cap = $4M
Quarterly Burn = $.37M
https://www.otcmarkets.com/filing/html?id=13902840&guid=7V9FUFzAdO58Zth
With neither stock having any substantial revenue, HTBX would need to dilute at 17 times that of NBIO...according to those numbers above
The Company has performed all necessary U.S. preclinical work and developed successful manufacturing techniques for PTB and is now ready to begin Phase 1 Brain Cancer studies.
The Company's response to COVID-19, indicating that Nascent is awaiting results from in vitro testing prior to the next step in its study of PTB and its use against viruses.
Collaboration with Manhattan BioSolutions Inc. in developing vaccines to be used against viruses around the world. The vaccine program employs a recombinant Bacillus Calmette-Guerin (rBCG), genetically engineered to express selected SARS-CoV-2 proteins. Based on preclinical experience with rBCG candidates for oncology indications and its safe track record as a tuberculosis vaccine, Nascent has the reason to believe that rBCG based vaccine against SARS-CoV-2 may be possible to develop.
Nascent expects to apply for grants based on the outcomes of in vitro studies and confirms that the company has requested a pre-IND meeting with the FDA to accelerate trials for the SARS-CoV-2 indications.
https://finance.yahoo.com/news/nascent-biotechs-ceo-provides-corporate-120000084.html
Trading at less than a $4M cap with an approx. $350K quarterly burn. I know you've been watching what the crazies can do to a stock that mentions anything positive re: covid19...and if they miss on the covid therapeutic in-vitro study and/or the vaccine collaboration resulting in the pps taking a nosedive, NBIO would remain a strong buy as the Phase 1 cancer would still be in play...
NBIO .11 - also has a Phase 1 "cancer treatment" + an ongoing covid in-vitro study awaiting an update + a covid vaccine collaboration...
The Company has performed all necessary U.S. preclinical work and developed successful manufacturing techniques for PTB and is now ready to begin Phase 1 Brain Cancer studies.
The Company's response to COVID-19, indicating that Nascent is awaiting results from in vitro testing prior to the next step in its study of PTB and its use against viruses.
Collaboration with Manhattan BioSolutions Inc. in developing vaccines to be used against viruses around the world. The vaccine program employs a recombinant Bacillus Calmette-Guerin (rBCG), genetically engineered to express selected SARS-CoV-2 proteins. Based on preclinical experience with rBCG candidates for oncology indications and its safe track record as a tuberculosis vaccine, Nascent has the reason to believe that rBCG based vaccine against SARS-CoV-2 may be possible to develop.
Nascent expects to apply for grants based on the outcomes of in vitro studies and confirms that the company has requested a pre-IND meeting with the FDA to accelerate trials for the SARS-CoV-2 indications.
https://finance.yahoo.com/news/nascent-biotechs-ceo-provides-corporate-120000084.html
Trading at less than a $4M cap with an approx. $350K quarterly burn. I know you've been watching what the crazies can do to a stock that mentions anything positive re: covid19...and if they miss on the covid therapeutic in-vitro study and/or the vaccine collaboration resulting in the pps taking a nosedive, NBIO would remain a strong buy as the Phase 1 cancer would still be in play...
APT 13.00 -
Revenue for the first quarter of 2020 increased 47.5% to $18.2 million...
As of May 1, 2020, the Company has booked approximately $46.8 million in orders for the Company’s N-95 face mask since January 27, 2020...
The Company has also seen a significant increase in orders of its face shield products since January 27, 2020, with orders totaling over $13.3 million as of May 1, 2020...
https://secfilings.nasdaq.com/filingFrameset.asp?FilingID=14125076&RcvdDate=5/6/2020&CoName=ALPHA%20PRO%20TECH%20LTD&FormType=8-K&View=html
$7 pps ain't happening here! And when our fearmongering-establishment-leaders cease their useless procrastinating about re-opening schools in the Fall, every youngster over the age of 2-years will be mandated to wear a disguise...
almost forgot - eps was .39 on that top much-much-smaller number of $18.2M. Makes one wonder what that previous pps spike to $40 was all about...
why...
They keep using the wording "deployed" in their pr...City of Greensboro, North Carolina has deployed two solar-powered EV ARC(TM) units... Makes one wonder if they're just giving them away for free lol?
I'll likely rejoin you here again asap...still waiting for some overall broadmarket dumpage and their new S-3-Filing lurks...
https://secfilings.nasdaq.com/filingFrameset.asp?FilingID=14204956&RcvdDate=6/8/2020&CoName=ENVISION%20SOLAR%20INTERNATIONAL%2C%20INC.&FormType=424B2&View=html
Kinda amazing how this held up thru the March deluge. Held strong above $6. Anyone still here?
SPRT - Ok gotcha and I like your number better...
SPRT - 28.4M Cash /minus/ 5.4M Total liabilities = 23M /divided by/ 19.5 OS = 1.18 netcash per share
https://secfilings.nasdaq.com/filingFrameset.asp?FilingID=14142852&RcvdDate=5/13/2020&CoName=SUPPORT.COM%2C%20INC.&FormType=10-Q&View=html
How do you arrive at the 1.40 number?
SPRT 1.25 - joined you long...close enough for me to being covid-related and the numbers are quite strong..
Netcash = $1.18
Tangible Book = $1.71
Q1 EPS = $.02
Seriously risk/reward advantageous...has anyone thought to mention SPRT at the stocktwits...
APT also up big today in sympatico with the covid-staples sector. Wondering if our fearfulmongering-establishment-politicians will allow ALL schools to re-open in the Fall? Wondering how many masks and foggings that would require...
why...
In this morning's goofiest of market strength, I entered July17 puts in PENN, BFAM, CBRL, TXRH, PLNT, and MAR
Just exited the last remaining CBRL position for a tidy profit and banked on all 6 of these trades. I can't remember going 6 for 6 in anything? The ludicrous 'buying' has become so mindless this simply cannot end well, longterm...
I had 1500 APT shares in a seldom used account that I had paid $13 for and was content to just wait for some news or the next filing. This morning premarket I entered a "Sell 15 June19 $14 @ .50" calls...to my surprise, it filled at .55. And you can still get .50 - gamble, gamble...gamble
It's these so-called analysts that concern me more - continuing to issue "buy recommendations" like cotton-candy-to-4-year-olds when 95% of companies are reporting "NO GUIDANCE"...so how can the analyst, with a straight face, pretend to know more about the company than the management...
APT - sweet! I'm showing they filed Q2 on 8/5/19 last year...
https://secfilings.nasdaq.com/filingFrameset.asp?FilingID=13572465&RcvdDate=8/5/2019&CoName=ALPHA%20PRO%20TECH%20LTD&FormType=8-K&View=html
...should be more great trade oppurtunities between now and then while (now even moreso after this LAKE update) fully expecting a blowout Q.
Some of the buying seems to be coming from bored individuals, some of whom hadn’t previously had much interest in trading but now have few sports, gambling or other activities to keep them occupied as the nation continues to deal with the coronavirus pandemic.
Dave Portnoy, founder of the popular website Barstool Sports, has turned to day trading, sharing regular proclamations to his 1.5 million Twitter followers as he scans his portfolio.
“Stocks only go up, this is the easiest game I’ve been part of!” he said in a video on June 4, with Dire Straits tunes in the background.
In an interview, Mr. Portnoy said in early June, when investor Warren Buffett said he sold his airline shares, Mr. Portnoy bought those stocks, a move that has led to big profits.
“It took me a while to figure out that the stock market isn’t connected to the economy,” he said. “I tell people there are two rules to investing: Stocks only go up, and if you have any problems, see rule No. 1.”
https://www.wsj.com/articles/individuals-roll-the-dice-on-stocks-as-veterans-fret-11591732784?mod=searchresults&page=1&pos=1
LAKE 23.50 / APT 12.50 - I bought LAKE into the previous filing and it was a total dud. Back then when LAKE was trading $15's and APT trading $13's, I liked APT waaayyyyyyy better...and still do
Long video at 17 minutes but WOW!!! How does this video have only 15.5K views? Candace Owens 100% gets it...
(scroll down to the June 3rd video - 17:11 minutes)
https://twitter.com/RealCandaceO
If I pasted Harold’s email to me here the stock would tank to $0.50
What is so top-secret about this email? Just post it, why be a procrastinator?
Good post...just a hint of "uplisting"...
NBIO .135 - https://www.nascentbiotech.com/snn-network-nascent-biotech-on-developing-covid-19-therapy-and-vaccine-collaboration-with-manhattan-biosolutions/
Pretty much the only covid-bio I still have an interest in. I see the risk/reward here as off-the-charts. NBIO has held an above .10cents pps for the previous 3 years...
https://bigcharts.marketwatch.com/quickchart/quickchart.asp?symb=nbio&insttype=&freq=2&show=&time=10
..without any 'coronavirus' or the insane DRUNKFEST amounts of cash thrown by the herd at covid-biotechs everytime they announce any update whatsoever...
INO 12.02 - they also filed a lawsuit against a supplier:
On June 3, 2020, Inovio Pharmaceuticals, Inc. (the “Company”) filed a complaint in the Court of Common Pleas of Montgomery County, Pennsylvania seeking, among other requests for emergency relief, to compel VGXI, Inc. and GeneOne Life Science, Inc. (together, “VGXI”) to facilitate the transfer of manufacturing methods, using VGXI’s technology, under the parties’ existing supply agreement (the “Supply Agreement”).
https://secfilings.nasdaq.com/filingFrameset.asp?FilingID=14197586&RcvdDate=6/3/2020&CoName=INOVIO%20PHARMACEUTICALS%2C%20INC.&FormType=8-K&View=html
Still only watching INO...might try to re-enter at $11-or less and expecting the covid-biotech sector will cease to be 'en fuego' as the threat of coronavirus subsides.
APT 9.66 - adding/flipping in this weakness. Story has not changed and still fully expect strong numbers upcoming for Q2 and going forward.
In this morning's goofiest of market strength, I entered July17 puts in PENN, BFAM, CBRL, TXRH, PLNT, and MAR
una panchanga loca, muchachas
TOMZ .77 - could have had all you wanted at .12 for the past years. Consolidation was, and still is, always in the cards. I flipped my second buy, .95, at 1.08 and rebought them this morning.
The story hasn't changed and disinfecting howard-hughes-germaphobe-style is here to staaaayyyyyyyyyyyyy! Can TOMZ hold whatever copyrights it owns and it's substantial lead on the competition is my only major concern?
PENN 40.40 (premarket) - setting an all-time-high...
https://bigcharts.marketwatch.com/quickchart/quickchart.asp?symb=penn&insttype=&freq=2&show=&time=20
...on these numbers...
https://old.nasdaq.com/symbol/penn/revenue-eps
...with NO guidance and an extremely dicey (pun intended) outlook...
The broad-market-herd drunkfest has now entered ludicrous speed.
Pfizer announces $500M investment in small-to-mid-cap therapeutic candidates today - doesn't mention any names.
The Pfizer Breakthrough Growth Initiative will focus on making non-controlling equity investments in clinical-stage public companies, with a primary focus on companies with small- to medium-sized market capitalizations across a range of therapeutic categories
https://finance.yahoo.com/news/pfizer-establishes-program-support-continued-100000984.html
I've got NBIO and COCP as 'therapeutic' longshot picks, so far, anyone know of other possible therapeutic candidates...preferrably those that have yet to spike-to-the-moon?
bigbird, you thinkin COCP might be on Pfizer's list of $500M recipients announced today?
The Pfizer Breakthrough Growth Initiative will focus on making non-controlling equity investments in clinical-stage public companies, with a primary focus on companies with small- to medium-sized market capitalizations across a range of therapeutic categories
https://finance.yahoo.com/news/pfizer-establishes-program-support-continued-100000984.html
I've got COCP and NBIO as 'therapeutic' longshot picks, so far, anyone know of other possible therapeutic candidates...preferrably those that have yet to spike-to-the-moon?